LMP776
Solid Tumors, Lymphomas
Phase 1Active
Key Facts
About Gibson Oncology
Gibson Oncology is a private, pre-revenue biotech founded in 2018, headquartered in Nashville, TN, with a significant operational presence in Miami, FL. Its lead asset, LMP744, has received FDA Orphan Drug Designation for glioblastoma and is entering a Phase II trial in collaboration with the NIH, leveraging its unique dual Top1/cMYC inhibition and ability to cross the blood-brain barrier. The company's broader pipeline includes additional licensed compounds (LMP400, LMP776) and an internally discovered oral class of Aza Indenoisoquinolines, targeting homologous recombination deficient cancers and offering potential synergy with PARP inhibitors.
View full company profile